To compare the efficacy Of raktavasechana ( jalaukavacharana ) and manjistha lepa On facial blemishes.

An open label randomized parallel trial to compare the efficacy of raktavasechana ( jalaukavacharana ) and manjistha lepa in vyanga patients. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/08/056716

Enrollment

Registered

2023-08-22

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma Health Condition 2: L599- Disorder of the skin and subcutaneous tissue related to radiation, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients presenting with classical signs and symptoms of vyanga were selected. 2. Age groups between 16-60 years were selected. 3. Both the sex. 4. Chronicity less than 2 years 5. Patients yogya for Lepa and raktavsechana. 6. Patient willing to sign the consent form. 7. Patient not taking any other medicine for Hyperpigmentation. 8. Patient with classical symptoms of vyanga.

Exclusion criteria

Exclusion criteria: 1. Patients ayogya for Lepa and raktavsechana. 2. Malignant melanoma 3. Acne Vulgaris,riehls melanosis, Poikiloderma of civtte. 4. Patients with other Systemic disorders. 5. Severe Anemia, pregnancy, any kind of noted drug allergy 6. Patient below the age 16 year and above 60 years. 7. Patient with Leprosy, Tuberculosis and Paralysis. 8. Hyperpigmentation caused due to any systemic disease such as Addisons disease, Cushing syndrome and Systemic lupus erythematous. 9. Patient with uncontrolled Hypertension/Cardiac problem/Diabetes Mellitus and any systematic disorder. 10. Hyperpigmentation since birth like Nevus of Ota and those caused by tumors such as malignant melanoma. 11. Exogenous ochronosis is a cutaneous disorder characterized by blue-black pigmentation resulting as a complication of long term application of skin lightening creams containing hydroquinone.

Design outcomes

Primary

Measure	Time frame
The outcome will be assessed on basis of improvement in MASI SCORE.Timepoint: At the baseline 30th & 60th day.	—

Secondary

Measure	Time frame
The outcome will be assessed on basis of improvement in sign & lesion color through color grading scale.Timepoint: at the baseline 30th & 60th day.	—

Countries

India

Contacts

Public ContactDr Kajal

Shri Krishna Ayush University Kurukshetra

drashishhmehta@gmail.com9468319930

Outcome results